Special Article

Clinical Pathway for Thyroidectomy☆,☆☆

Jesús María Villar del Moral,a,* Víctor Soria Aledo,b Alberto Colina Alonso,c Benito Flores Pastor,b María Teresa Gutiérrez Rodríguez,d Joaquín Ortega Serrano,e Pedro Parra Hidalgo,f Susana Ros Lópezg

a Sección de Cirugía Endocrina de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Universitario Virgen de las Nieves, Granada, Spain
b Sección de Gestión de Calidad de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Universitario Morales Meseguer, Murcia, Spain
c Sección de Gestión de Calidad de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Universitario de Cruces, Baracaldo, Vizcaya, Spain
d Sección de Cirugía Endocrina de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Universitario de Basurto, Bilbao, Spain
e Sección de Cirugía Endocrina de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Clínico Universitario de Valencia, Valencia, Spain
f Sección de Gestión de Calidad de la Asociación Española de Cirujanos, Consejería de Sanidad de la Región de Murcia, Murcia, Spain
g Sección de Cirugía Endocrina de la Asociación Española de Cirujanos, Servicio de Cirugía General, Hospital Universitario Arnau de Vilanova, Lérida, Spain

ARTICLE INFO

Article history:
Received 22 July 2014
Accepted 29 November 2014
Available online 16 April 2015

Keywords:
Thyroidectomy
Clinical pathway
Postoperative hypocalcemia
Recurrent laryngeal nerve
Morbidity
Hospital stay
Outpatient thyroidectomy

ABSTRACT

Clinical pathways are care plans applicable to patient care procedures that present variations in practice and a predictable clinical course. They are designed not as a substitute for clinical judgement, but rather as a means to improve the effectiveness and efficiency of the procedures. This clinical pathway is the result of a collaborative work of the Sections of Endocrine Surgery and Quality Management of the Spanish Association of Surgeons. It attempts to provide a framework for standardising the performance of thyroidectomy, the most frequently performed operation in endocrine surgery. Along with the usual documents of clinical pathways (temporary matrix, variance tracking and information sheets, assessment indicators and a satisfaction questionnaire) it includes a review of the scientific evidence around different aspects of pre, intra and postoperative management. Among others, antibiotic and antithrombotic prophylaxis, preoperative preparation in hyperthyroidism, intraoperative neuromonitoring and systems for obtaining hemostasis are included, along with management of postoperative hypocalcemia.

© 2014 AEC. Published by Elsevier España, S.L.U. All rights reserved.

☆☆ Some information for this Clinical Pathway for Thyroidectomy was publicly announced on October 25, 2013, during the XIX National Meeting of Surgery held in Burgos.
* Corresponding author.
E-mail address: jesusm.villar.ssapa@juntadeandalucia.es (J.M. Villar del Moral).

2173-5077/ © 2014 AEC. Published by Elsevier España, S.L.U. All rights reserved.
Vía clínica de la tiroidectomía

RESUMEN

Las vías clínicas son planes detallados de asistencia aplicables al tratamiento de pacientes con variaciones en la práctica y un curso clínico predecible. Sin pretender sustituir el juicio clínico de los profesionales, buscan una mejora en la efectividad y la eficiencia. La vía clínica que presentamos es el resultado del trabajo colaborativo de las Secciones de Cirugía Endocrina y Gestión de Calidad de la Asociación Española de Cirujanos, que intenta aportar un marco para normalizar la realización de la tiroidectomía. Junto con documentos habituales de toda vía clínica (matriz temporal, hoja de variaciones e información, indicadores de evaluación, encuesta de satisfacción), incluye una revisión de la evidencia científica en torno a diferentes aspectos del pre, intra y posoperatorio de esta intervención, la más frecuentemente realizada en cirugía endocrina. Entre otros, analiza la profilaxis antibiótica y antitrombótica, la preparación preoperatoria en hipertiroidismo, la neuromonitorización intraoperatoria, los sistemas para hemostasia intraoperatoria y el tratamiento de la hipocalcemia posoperatoria.

© 2014 AEC. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Justification and Objectives of the Clinical Pathway

Any health care process requires a multidisciplinary and comprehensive approach. To that end, one of the tools available to health care professionals is clinical practice pathways and guidelines. Clinical pathways are health care plans applicable to patients with a specific disease that coordinate every dimension of the health care quality: those estimated by professionals (scientific–technical quality, inter-professional health care and coordination optimisation), by patients (information, participation and expectations adjustment) and by agents (efficiency and continuous assessment). These are tools that help to facilitate the multidisciplinary and systematised assistance to the patient but do not replace professional clinical judgement. The main objectives are the following: standardise professional performance in accordance with the best scientific evidence available, to reduce the unjustified variability of clinical practice and unnecessary costs associated to the procedure.

Thyroidectomy is the intervention most frequently performed in endocrine surgery, and has evolved in the last years, with a better knowledge of the pathophysiology of its complications and the incorporation of new assistance techniques in the pre-, intra- and postoperative scenarios. With the purpose of helping professionals incorporate the best practices and provide the best assistance to patients, the Endocrine Surgery and Quality Management sections of the Asociación Española de Cirujanos (Spanish Association of Surgeons) decided to create a clinical pathway for thyroidectomy (CPT). The boards of both sections assigned its performance to a joint and equal group of work. This clinical pathway is intended to become a useful tool in clinical decision-making, through a series of evidence-based guidelines with which the problems arising from the care of particular patients are solved.

Process Limits. Inclusion and Exclusion Criteria

The clinical pathway starts when the surgeon confirms the surgical indication and advises the patient to have a thyroidectomy performed. Even though conceptually the exit limit is the hospital discharge, due to the existing variability in practice, we have incorporated a systematic review of certain innovative or controversial monitoring aspects, the follow-up and the eventual treatment of postoperative complications, once the patient has been discharged. Generally, the recommendations proposed in the CPT are applicable to all the patients subjected to thyroid resection. Exclusion criteria have been defined as: regional or general anaesthesia contraindication, urgent interventions and the performance of concomitant larger surgical procedures. The CPT has been divided into 2 basic documents: recommendations on key process points and CPT-related documents.

Recommendations on Key Process Points

General Considerations

They have been systematically prepared regarding high-variability aspects or aspects that required an update. The evidence-based medicine methodology has been followed, standardising the search and performing a critical assessment of the literature. Based on the level of evidence (LOE) determined, we have appraised several recommendations to minimise bias. We have based our work on original documents and clinical practice guidelines assessed in accordance with the guidelines from Appraisal of Guidelines for Research and Evaluation–AGREE–II (http://www.agreetrust.org).

The LOE classification used is the one from the Oxford Centre for Evidence-Based Medicine in 2009 (http://www.
include factors. 

- Grade A: derived from level 1 consistent studies.
- Grade B: derived from level 2 to 3 consistent studies or extrapolations (use of data for clinical situations with potentially major differences) of level 1 studies.
- Grade C: derived from level 4 studies or extrapolations of level 2–3 studies.
- Grade D: derived from level 5 evidence or from inconsistent or non-conclusive studies of any level.

Preoperative Aspects

Medical Records and Physical Examination
Information regarding family history of cancer or endocrine disease, irradiation or prior cervical surgery, node growth rate, presence of compressive symptoms (dyspnoea, dysphagia and dysphonia) and hyper or hypothyroidism has to be collected \(^5\) (LOE 2b, GR B). The absence of symptoms does not rule out malignancy \(^6\) (LOE 3b, GR C). The physical examination has to include the thyroids and cervical lymph nodes (LOE 3b, GR B), and a description of their characteristics and location \(^5\)–\(^7\) (LOE 3b, GR C).

Laboratory Studies

The thyrotropic hormone serum level must be determined since it indicates the hormonal status \(^6\) (LOE 1b, GR A). Its descent indicates hyperthyroidism, excludes the risk of neoplasm and evidences the pertinence of a scintigram (LOE 2b, GR B). An increased TSH makes it advisable to determine anti-TPO antibodies. Antithyroglobulin antibodies must be determined if there is a suspicion of lymphocytic thyroiditis, with normal TPO concentrations (LOE 3b, GR C). The determination of thyroglobulin is not preoperatively justified. \(^5\)–\(^6\)

Besides the standard determinations, we would include liver function tests \(^8\) (LOE 5, GR D), calcium tests and phosphorus tests. \(^9\) The determination of parathyroid hormone (PTH) allows us to rule out hyperparathyroidism and count on the postoperative descent gradient as a hypocalcaemia predictor. Therefore, its systematic determination is recommended. Within the same context, the determination of vitamin D 25-OH is also useful and, therefore, its determination is also proposed for all patients.

There is no consensus regarding the routine determination of baseline calcitonin to rule out medullary carcinoma. \(^10\)–\(^11\) This would be cost-effective in hereditary syndromes, single solid nodules, whenever there is family history of thyroid cancer or suspicion of malignancy or medullary carcinoma in the fine-needle puncture. \(^5\)–\(^7\)–\(^12\) Therefore, it is recommended restrictedly in these clinical scenarios (LOE 3b, GR B). Elevated figures must be confirmed with a calcium or pentagastrin (contraindicated in pregnant women) stimulation test. \(^13\)

A blood cross match has to be anticipated in interventions for anaplastic cancers or advanced tumours requiring extensive cervical dissections, though, given the low LOE available

### Table 1 – Levels of Evidence and Grades of Recommendation From the Oxford Centre for Evidence-Based Medicine (March, 2009).

<table>
<thead>
<tr>
<th>Level</th>
<th>Aetiology/Treatment/Adverse effects/Prevention</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Homogeneous SR(^a) of clinical trials</td>
<td>Homogeneous SR(^a) of level 1 diagnostic studies or algorithms of decision or rating scales derived from 1b studies from different clinical centres</td>
</tr>
<tr>
<td>1b</td>
<td>Clinical trial with narrow confidence interval</td>
<td>Diagnostic test validating cohort studies(^b) with good reference standards, or algorithms of decision or rating scales tested in one clinical centre</td>
</tr>
<tr>
<td>1c</td>
<td>“All or none” cases-series(^c)</td>
<td>Highly specific and sensitive diagnostic test</td>
</tr>
<tr>
<td>2a</td>
<td>Homogeneous SR(^a) of cohort studies</td>
<td>Homogeneous SR(^a) of level 2 diagnostic studies or higher</td>
</tr>
<tr>
<td>2b</td>
<td>Individual cohort studies or poor-quality clinical trials (&lt;80% follow-up)</td>
<td>Validating cohort study(^d) with good reference standards. Studies derived from algorithms of decision or rating scales, or validated only upon divided samples(^e) or databases</td>
</tr>
<tr>
<td>2c</td>
<td>Outcomes Research or ecological studies</td>
<td>Homogeneous SR(^a) of Level 3b studies or higher</td>
</tr>
<tr>
<td>3a</td>
<td>Homogeneous SR(^a) of case-control studies</td>
<td>Non-consecutive patients study, or without a consistently applied reference standard</td>
</tr>
<tr>
<td>3b</td>
<td>Individual case-control studies</td>
<td>Case-control studies with poor or non-independent reference standards</td>
</tr>
<tr>
<td>4</td>
<td>Case-series or poor-quality case-control studies(^a)</td>
<td>Expert opinion without explicit critical assessment, or based on physiology, (ex) (vivo) research or general principles</td>
</tr>
<tr>
<td>5</td>
<td>Expert opinion without explicit critical assessment, or based on physiology, (ex) (vivo) research or general principles</td>
<td></td>
</tr>
</tbody>
</table>

**SR:** systematic reviews.

\(^a\) Free of worrisome variations in the direction and degree of results between individual studies.

\(^b\) Validating studies to test the reliability of a specific diagnostic test, based on prior evidence.

\(^c\) Independent of the test and applied to all patients.

\(^d\) Sample separately obtained and then artificially divided into a study and validation group.

\(^e\) Study that fails to clearly define compared groups and/or fails to measure exposures and effects in both groups in the same objective way (preferably blinded) and/or fails to identify or appropriately control confounding factors.
on this matter, the implementation should always be approved by the Transfusion Commission or the appropriate authority for each specific centre (LOE 5, GR D).

**Imaging Tests**

The first exploration test to be performed is cervical ultrasound: it is harmless, cheap and it can be performed during the office visit (LOE 1c, GR A). It provides a lot of information on the glands size and echogenicity. It will describe the presence or absence of nodules, their number, size, location, shape, margins, content, echographic pattern, vascularisation and presence of calcifications.\(^5,6\) (LOE 2b, GR C).

It explores the presence of adenopathies, vascular abnormalities, cysts and other malformations.\(^5,14,15\) The elastography and the contrast-enhanced ultrasound may be useful to determine the benignity or malignancy of the thyroid nodule, but they are not currently a part of the study protocol\(^5,6\) (LOE 2b, GR C).

Neither magnetic resonance imaging nor computed tomography is routinely indicated since they are less cost-effective and informative than the ultrasound\(^1\) (LOE 5, GR D). They should be ordered in cases of compressive symptoms, suspicion of endothoracic extension or retrovisceral location. In case of malignity, they allow for the detection of adenopathies, local infiltration or distant metastasis. With this last purpose in mind, magnetic resonance imaging (or computed tomography without intravenous contrast) is mostly chosen because the iodinated contrast used for the computed tomography interferes with the possible postoperative use of radioiodine\(^6\) (LOE 5, GR D).

Positron emission tomography would mostly be useful in cases of suspicion of recurrence of thyroid cancer, undetected by conventional techniques. In the preoperative study, more than one third of the cases of an incidental focal thyroid uptake correspond to carcinomas. In nodules with follicular neoplasmy cytology, it has shown discriminative capabilities due to its high sensitivity, although with low specificity.\(^5,16\)

However, its systematic use cannot be recommended (LOE 2b, GR B).

The thyroid scintigam is not routinely indicated. It is mainly used for the study of hyperthyroidism\(^5,6,9\) (LOE 2b, GR B). In the solid nodule with undetermined cytology, hyperfunction makes it more unlikely to be carcinoma. It must never be used in pregnant women.

**Fine-Needle Aspiration-Puncture**

Cytological study is the test of choice for the diagnosis of non-hyperfunctioning thyroid nodules.\(^5,6,10,17\) The performance of the fine-needle aspiration-puncture (FNAP) under echographic control, the collection of sufficient sample and the examination by expert cytologists improve its performance (LOE 2b, GR B). FNAP is not indicated in infracentimetric nodules, except in the case of echographic findings indicative of malignancy. In the case of cystic-solid lesions, the solid component must be punctured and, in multinodular glands, the nodule most suspicious of malignancy, regardless of size. (LOE 5, GR D).\(^17\)

Globally, 72% of FNAP end up being benign, 5% malignant, 17% undetermined and 6% are failed tests due to insufficient or inadequate sample.\(^18\) Currently, the Bethesda cytology classification is the one that is most widely used (Table 2 of Annex 1, supplementary material available on electronic issue).\(^19\) As we can see, it establishes 6 diagnostic categories, for which it constitutes a risk of malignancy (with percentages supported by a wide range of subsequent studies\(^20,21\)) and a clinical recommendation (LOE 2b, GR B).

The FNAP allows for the diagnosis of anaplastic, medullary and papillary carcinoma, thyroid lymphoma and metastases, but not for the diagnosis of follicular carcinomas\(^17,18\) (LOE 5, GR D). A thick-needle biopsy may offer additional information on cervical masses and thyroids presenting non-conclusive results in the FNAP\(^22\) (LOE 2b, GR B).

**Laryngoscopy**

The preoperative verification of mobility of the vocal cords, either via fibro-laryngoscopy, or via indirect laryngoscopy, may help in deciding the surgical strategy\(^7\) (LOE 5, GR D). Even though all authors acknowledge its usefulness, they usually admit that they do not perform it routinely. Due to the low LOE available and the limited profitability of this technique in asymptomatic patients from the vocal point of view and without medical background that could be linked to a laryngeal motility disorder, we cannot recommend it routinely. It must always be requested under the following circumstances:

1. In the case of history of cervical or thyroid surgery.
2. If the patient presents dysphonia or changes in the voice tone.
3. Whenever an intraoperative neuromonitoring is to be performed.
4. In cases of malignant or possibly malignant condition. In cases of advanced or anaplastic cancer, it should be supplemented with bronchoscopy and esophagoscopy.\(^23\)
5. In benign disease, whenever a greater risk of recurrence is foreseen, as in large endothoracic goitre with tracheal displacement or compression (LOE 4, GR C).

**Preoperative Preparation in Hyperthyroidism**

Patients must arrive euthyroid to the surgery, so antithyroid medication should not be preoperatively suspended\(^24\) (LOE 5, GR D). Occasionally, beta-blockers (propanolol) may be necessary for a better symptomatic control.\(^25\) The current antithyroid medication may have made unnecessary the preoperative use of Lugol’s solution in Graves-Basedow disease\(^26–29\) (LOE 5, GR D).

**Molecular Biology and Genetic Study**

It is performed on thyroid tissue samples. It may be useful in thyroid nodules with undetermined cytology. BRAF and RAS genes (N-RAS, H-RAS and K-RAS), and abnormal reorganisation type RET/PTC constitute the most studied somatic mutations associated with differentiated thyroid cancer. The gene expression for determination of messenger RNA or microRNA is also analysed.\(^17,30\) These are expensive determinations, with non-validated results, undefined usefulness and selective usage, although its medium-term incorporation to algorithms of decision is foreseen (LOE 2b GR B). On the other hand, mutational tests are essential upon
suspicion of polyglandular syndromes (MEN2), in relation with the RET proto-oncogene.31

Intraoperative Aspects

Antibiotic Prophylaxis

It is intended to reduce local bacterial load during the procedure.32 The surgical site infection incidence varies depending on the surgery type and location. If there is no prior tissue inflammation and the integrity of the aero-digestive tract is maintained, thyroidectomy should be considered a clean surgery that does not require antibiotic prophylaxis.33–35 The use of antibiotics in some patients with risk factors would be justified, when at least one of these is present: cancer, associated lymphadenectomy, airway opening, prolonged surgery or presence of at least one clinical risk factor: prior cervical radiation, recent chemotherapy, advanced age, malnutrition, diabetes mellitus, obesity, smoking, anaemia, peripheral vascular disease, immunosuppression74 (LOE 3a, GR C). It will be administered in single dose before cutaneous incision and it must cover the most common pathogens in this area (Gram-positive cocci, including streptococcus species, negative coagulase staphylococcus and Staphylococcus aureus).39,40

Antithrombotic Prophylaxis

There are well-known risk factors for venous thromboembolism.41,42 Several models stratify such risk,43–45 such as Caprini (Supplementary material, Table 3 of Annex 1).45 This and the haemorrhage risk assessment46 are recommended to decide on prescribing thromboembolic prophylaxis. The guideline to antithrombotic therapy of the American College of Chest Physicians includes thyroidectomy in the same risk group as breast, urological and intestinal surgery and establishes some applicable therapeutic recommendations (Supplementary material, Table 4 of Annex 1).47

Most patients submitted to thyroidectomy are of at least moderate risk. On the other hand, pharmacological prophylaxis may increase the risk of haemorrhage in thyroid surgery up to 0.5%.48 Recent assessments of risk-benefit ratio recommend the preservation of pharmacological thromboembolic prophylaxis for high-risk patients, with c5 or more points as per Caprini’s model of risk stratification for venous thromboembolism49,49 (LOE 2a, GR B).

Antinauseant Prophylaxis

Postoperative vomiting and nausea appear in up to 71% of the cases after a thyroidectomy.50,51 They cause patient discomfort and an increase in venous pressure that compromises vascular ligatures or sealing areas, favouring haemorrhages. Preoperative dexamethasone reduces its incidence, the pain and the need for analgesics and it improves vocal function.52–54 The routine prophylactic use of antinauseant agents with a single preoperative dose of 8 mg of dexamethasone is recommended55 (LOE 1a, GR A).

Haemostasis

It is mandatory to verify haemostasis after finishing the thyroid resection. Venous haemorrhage may be evidenced with Valsalva manoeuvres, applying positive expiratory pressure in the ventilation circuit. The Trendelenburg position at 30° assists in identifying additional bleeding points56 (LOE 2b, GR B). Cervical compression bandaging is not useful and makes it difficult to visualize a possible haematoma, so their use is not justified57 (LOE 1b, GR A).

Besides the classic haemostasis systems, we have new devices, such as the ultrasound energy system and the bipolar electrothermal vessel sealing system. In several meta-analyses, their use is advantageous over conventional systems regarding operating time, intra- and post-operative haemorrhage and hospital stay (LOE 1a, GR A).58–61 The current limited evidence does not allow for the extraction of recommendations regarding the advantages of using one of these devices over the other.62–68

The application of sealing and local haemostatic drugs (mainly fibrin-based) has been proposed. They may be useful to improve haemostasis and prevent postoperative seromas. In several studies, they reduce the debit measured in drainages,68 they prevent their use and reduce hospital stay.69–73 However, the products used are not comparable, the studies are limited and reduced on a case by case basis so their systematic application is not justified73 (LOE 2b, GR B).

Intraoperative Biopsy

It is not useful to rule out malignancy in lesions with cytology result of follicular neoplasm, since a detailed analysis is required to determine a vascular or capsular invasion.74,75 It would not be cost-effective in patients with a diagnostic FNA of papillary carcinoma either.76–78 Some studies have raised awareness on the possible effect produced by frozen sections of the surgical specimen, that could alter the identification of vascular and capsular invasion, nuclear changes and the detection of microcarcinomas.74,75 Therefore, its systematic use is not recommended in thyroid nodule surgery. It should be reserved for cases of cytological suspicion of malignancy, unexpected intraoperative findings indicative of cancer or diagnostic confirmation of not very frequent lesions (LOE 2C, GR D).

Intraoperative Neuromonitoring

Since the beginning of the xx century, the routine identification of the recurrent laryngeal nerve during thyroidectomy has been recommended to reduce its lesions.79 Moreover, the preservation of the external branch of the superior laryngeal nerve, anatomically related to the superior thyroid artery, is desirable.80

The introduction of intraoperative neuromonitoring in thyroid surgery is recent. In the most widely used method, an endotracheal tube with electrodes in the external part gathers the effect of the recurrent nerve stimulation through the contraction of the vocal cords. Its usage requires a preoperative and a postoperative laryngoscopy.81 Among other advantages, we can include:

1. It may prevent bilateral recurrent lesion, if the surgeon does not act on the second side after verifying a loss of electromyographic signal in the former.82,83
2. It may be specially useful in re-interventions, for surgeons with low volume of activity and from the medical-legal and teaching viewpoint.84,85
Some disadvantages have also been described:

1. Its usage does not prevent recurrent paralysis since it only predicts it when a lesion has already occurred.\(^{85,86}\) Vagal nerve continuous stimulation could detect reversible electromyographic changes, but the results are not tested in a reliable manner.\(^{87}\)
2. It has a low positive predictive value.\(^{88}\) Upon loss of signal, the possibilities of paralysis are 30%–75%. Some of the causes of false positives are endotracheal tube displacement, equipment problems, a blood-filled surgical field and persistence of neuromuscular blockade.
3. Its usage may delay total thyroidectomy to a second surgery. In up to 90% of the patients without nervous section, acting on the second side would not add risk due to intraoperative recovery of the nerve function.\(^{89}\)
4. It is doubtfully cost-effective. It does not reduce operating time and adds direct costs and operating room time.\(^{88}\)

Two meta-analyses analyse its usefulness.\(^{84,85}\) One did not show nervous lesion rates reduction after its use.\(^{84}\) In the other one,\(^{85,86,90-94}\) it only reduced significantly the risk of transient lesion of the external branch of the superior laryngeal nerve. Taking this information into account, we cannot recommend its routine usage (LOE 5, GR D).

**Parathyroid Autogenous Transplantation**

The parathyroid autogenous transplantation in the sternocleidomastoid muscle is a widely spread manoeuvre, although there are doubts regarding its actual degree of usefulness.\(^{95}\) In principle, it is only indicated when any gland has been totally devascularised or has been inadvertently removed. The best prevention is to maintain the glands in situ and vascularise them with a thorough technique, since the permanent hypoparathyroidism rate significantly increases after autogenous transplantation of more than 2 glands.\(^{95}\) (LOE 4, GR C).

**Use of Drainages**

It may be avoided practically in 90% of thyroidectomies,\(^{96}\) since:

- They do not prevent haemorrhage or make the possible re-intervention any faster.
- Its limited debit does not rule out haematoma, since they may be obstructed with clots.
- They do not prevent postoperative seromas and collections.
- They may increase the surgical wound infection rate.
- They cause patient discomfort and prolong hospital stay.

In summary, as gathered in the review of the Cochrane Collaboration (valid for patients without thyroid endothoracic extension, coagulopathy or lymph node dissections), they do not offer benefits and are unnecessary.\(^{97-99}\) Therefore, their use is selectively recommended (LOE 1a, GR A).

**Postoperative Aspects**

**Recovery Room Stay**

The minimum period of stay recommended is 6 h.\(^{100,101}\) (LOE 5, GR D). Possible complications, such as nausea and vomiting, pain, alterations in the respiratory function (breathing difficulty, laryngeal stridor) and cardiovascular alterations, haemorrhage causing asphyctic haematoma and other complications can be treated.\(^{101,102}\) In the absence of complications, an oral intake 4–6 h after surgery may be initiated, preferably on demand.\(^{103-106}\) (LOE 2b, GR B).

**Monitoring of the Parathyroid Function and Treatment of Hypocalcaemia**

Hypocalcaemia is the most frequent complication after a bilateral thyroidectomy. It occurs transiently in 30% of the patients and stays permanently (after surgery) in 2%. Its symptoms may start up to 72 h after the thyroidectomy. Test procedures are required to rule it out prematurely (LOE 2a, GR B).\(^{107-110}\) Due to its minimum incidence, they would not be cost-effective after hemithyroidectomy.\(^{111}\)

The tendency to perform ambulatory surgery\(^{112,113}\) has encouraged the development of several modalities for its premature detection.\(^{114-117}\) The isolated determination of calcium would have a maximum reliability at 72 h, increasing hospital stay. Total corrected calcium may be measured with total protein and albumin (more affordable and extended) or the ionised.\(^{117,118}\) The measurement of PTH figures, taken during the first 24 h after thyroidectomy, is useful to predict hypocalcaemia.\(^{119}\) (LOE 2a, GR B). Associated to calciumia, it provides maximum reliability.\(^{119-125}\) Since its reference values and measurement units vary,\(^{120}\) its relative level of descent is more easily generalised as of the preoperative to postoperative values,\(^{126}\) with the most predictive gradient located at 40%–75%.\(^{110,119,120,126-128}\)

If we lack PTH figures, we may establish a cut-off point of 15 pg/mL. Patients with higher values will not need calcium if they present calciumia higher than or equal to 8 mg/dL and they will be treated with low doses of calcium if they present calciumia below 8 mg/dL.

Reposition should be more aggressive, including calcitriol, in the case of PTH figures below 15 pg/mL.

Therapeutic strategies in the cases of hypocalcaemia include the selective or routine reposition (depending on targeted needs) of oral calcium, associated to calcitriol or not, the active form of vitamin D. This association is more effective but requires a closer monitoring to prevent hypercalcemia.\(^{119-123}\) (LOE 2b, GR B). Intravenous calcium is reserved for very symptomatic patients or patients with calcium below 7–7.5 mg/dL.\(^{133-136}\) It must be associated to oral treatment to regularise calcium more rapidly (LOE 2b, GR B). For oral replacement, the more recommended compounds are carbonate or calcium citrate. For the intravenous treatment (in slow perfusion), calcium gluconate, in 10 ml ampoules at 10% containing 93 mg of elemental calcium is preferred. Another option is calcium chloride in 10 ml ampoules at 10% containing 270 mg of elemental calcium, although it has more adverse effects.

In the cases of untreatable or serious hypocalcaemias, a concomitant hypomagnesemia (levels of Mg <0.7 mEq/L or 1.4 mg/dL) should be ruled out. For a rapid reposition, an intravenous treatment is required.\(^{137-138}\) though oral reposition is always preferred. The urgent treatment (intravenous) is performed by immediately administering 6–12 mmol/L of magnesium sulfate (Sulmetin\(^{16}\)), and 40 mmol in the following 5 h. A phial contains 150 mg, 12 mEq or 6 mmol of Mg\(^{2+}\). 1–2 phials
should be administered in 10–20 min (never one phial in less than 10 min). Orally, 15 mmol/day should be administered (around 400 mg of magnesium oxide). Supplementation must be maintained until oral intake improves and magnesium is higher than 2 mg/dL. There is more hypocalcaemia in patients with preoperative vitamin D deficiency so it would be advisable to maintain their preoperative levels within adequate ranges. 135,136,140

In conclusion, to minimise the risk of hypocalcaemia and favour one-day postoperative stays, we propose the joint determination of calcaemia (the day after the intervention) and postoperative PTH (extracted 4–24 h after the end of the surgery, based on the centres availability). For this last one, a gradient descent of 65% of its preoperative value shall be considered to indicate substitution treatment. 127 If there was a higher probability of hypocalcaemia due to intraoperative incidences, an oral “prophylactic” treatment may be prematurely established. The recommended reposition guidelines are presented in Fig. 1.

---

**Fig. 1 – Therapeutic algorithm for calcium reposition.** Amp: ampoules; Ca: calcium; Cac: corrected calcium. i.v.: intravenous; DS: dextrose solution; p.o.: per os (oral administration); PTH: parathyroid hormone; TSH: thyrotropic hormone.

*Calcaemia can be measured with total corrected calcium (with proteins or albumin) or with ionic calcium. The values proposed herein pertain to corrected calcium.

**The doses reflected pertain to elemental calcium.

***Appraise admission in very symptomatic patients or in patients with severe signs of hypocalcaemia, distance or difficult access to health care centre or prediction of difficulty in ambulatory handling.

****Appraise calcaemia figures and weight.
Hospital Stay
The current standard is at least one-night postoperative hospitalisation (LOE 5, GR D), and the minimum period of hospital observation is 6–8 h. Ambulatory surgery is possible for selected patients. The American Thyroid Association has proposed relative contraindications (Supplementary material, Table 5 of Annex 1) and some conditions the patient must meet before ambulatory hospital discharge are:

1. Ability to drink fluids and take oral medication.
2. Adequate pain control with oral analgesics.

Clinical pathway for partial or total thyroidectomy.

Hospital …………………..

Digestive system and general surgery department.

Expected hospital stay: 1 day (to balanced ASA I, II, and III patients).

<table>
<thead>
<tr>
<th>Level of care</th>
<th>Before admission</th>
<th>Day of surgery</th>
<th>Day + 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Check-ups</td>
<td>At admission, review of preoperative and informed consent (surgeon, anaesthetist and nurse), last thyroid hormones, TA and T3. Fastening verification and verification of suspension of antiplatelet and/or anticoagulant drugs.</td>
<td>Appraising of clinical signs of hypocalcaemia and/or airway compression. Appraising of permeability, debit and drainage aspect. Vital signs every eight hours.</td>
<td>Drainage aspect and debit (if present). If it is haematoic and &gt;50 ml in 24 hours, do not remove and rule out cervical haematoma.</td>
</tr>
<tr>
<td>Diagnostic tests</td>
<td>Standard blood tests. TSH, calcium and phosphorus, PTH, 25 (OH) vitamin D. Chest Rx, EKG.</td>
<td>Postsurgical PTH.</td>
<td>PTH (if it was not performed the day before), plasma calcium and total proteins at 8:00 hours.</td>
</tr>
<tr>
<td>Physical activity</td>
<td>Normal</td>
<td>Seat on chair as of 6 hours after intervention. Encourage wandering.</td>
<td>Normal wandering.</td>
</tr>
<tr>
<td>Medication and treatments.</td>
<td>LMWH sc. the previous afternoon (selective use). Four preoperative days if anticoagulant drugs are suspended. Oral Benzodiazepine the night before. Lugol’s solution at 5%. 5 drops dissolved in water / 8 hours, the 7 days prior to the intervention for patients with Graves-Basedow disease (optional).</td>
<td>Antibiotic prophylaxis in case of diabetes, immunosuppression, prolonged surgery or cervical dissection. Intraoperative antiemetic prophylaxis with ondansetron and intravenous dexamethasone. Selective antithrombotic prophylaxis. Maintain peripheral venous line. Intravenous analgesia scheduled every 4-6 hours.</td>
<td>Oral analgesics scheduled every 8 hours. Remove line once normal calcaemia has been verified. Levotyroxine: one 50 micrograms tablet per day. A week later, switch to 1.6 mcg/kg of weight per day until reviewed by Endocrinology department.</td>
</tr>
<tr>
<td>Hypocalcaemia correction:</td>
<td>Fasting since 8 hours before intervention.</td>
<td>See Figure 1.</td>
<td>See Figure 1. Objective: Prevent symptoms and maintain corrected serum calcium &gt;8.</td>
</tr>
<tr>
<td>Nutrition.</td>
<td>Fasting since 8 hours before intervention.</td>
<td>Fluids since 6 hours after surgery, progressing to bland diet.</td>
<td>Bland diet.</td>
</tr>
<tr>
<td>Information and support.</td>
<td>Information to patient and family about diet, activity, wound care, medication, appointments and check-ups.</td>
<td>Postoperative information on intervention and foreseeable postsurgical course (possible discharge the following day).</td>
<td>Evolution information. Discharge conditions: No bleeding, asphyctic haematoma, nausea, vomiting vertigo or hypocalcaemia symptoms. Ca++ corrected &gt;7.5. Normal deglutition and breathing, pain controlled.</td>
</tr>
<tr>
<td>Objectives</td>
<td>Minimise suspensions, complications and stay.</td>
<td>Minimise pain, reduce complication rate.</td>
<td>Hospital discharge, avoid re-admissions.</td>
</tr>
</tbody>
</table>

Note: These instructions may be altered based on the patient’s specific conditions.

Fig. 2 – Process time matrix.
Clinical pathway for partial or total thyroidectomy.

Hospital ....................

Digestive system and general surgery department.

Expected hospital stay: 1 day (to balanced ASA I, II, and III patients).

<table>
<thead>
<tr>
<th>Level of care</th>
<th>Before admission</th>
<th>Day of surgery</th>
<th>Day + 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Check-ups</td>
<td>At admission, review of preoperative and informed consent (surgeon, anaesthetist and nurse), last thyroid hormones. Fasting verification and verification of suspension of antiplatelet and/or anticoagulant drugs.</td>
<td>Appraising of clinical signs of airway compression. Appraising of permeability, debit and drainage aspect. Vital signs every eight hours.</td>
<td>Drainage aspect and debit (if present). If it is haematic and &gt; 50 ml in 24 hours, do not remove and rule out cervical haematoma.</td>
</tr>
<tr>
<td>Diagnostic tests</td>
<td>Standard blood tests. Calcium and TSH. Chest x-ray, EKG.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication and treatments.</td>
<td>LMWH sc. the previous afternoon (selective use). Maintain during 4 preoperative days if anticoagulant drugs are suspended. Oral Benzodiazepine the night before.</td>
<td>Antibiotic prophylaxis in case of diabetes, immunosuppression or prolonged surgery. Intraoperative antiflammatory prophylaxis with ondansetron and intravenous dexamethasone. Antithrombotic prophylaxis (selective use). Maintain peripheral venous line. Intravenous analgesia scheduled every 4-6 hours</td>
<td>Oral analgesics scheduled every 8 hours. Remove intravenous</td>
</tr>
<tr>
<td>Nutrition.</td>
<td>Fasting since 8 hours before intervention.</td>
<td>Fluids since 6 hours after surgery, progressing to bland diet.</td>
<td>Bland diet.</td>
</tr>
<tr>
<td>Information and support.</td>
<td>Information to patient and family about diet, activity, wound care, medication, appointments and check-ups.</td>
<td>Postoperative information on intervention and foreseeable postsurgical course (possible discharge the following day).</td>
<td>Evolution information. Discharge conditions: No bleeding, cervical haematoma, nausea, vomiting or vertigo. Normal deglutition and breathing.</td>
</tr>
<tr>
<td>Objectives</td>
<td>Minimise suspensions, complications and stay.</td>
<td>Minimise pain, reduce complication rate.</td>
<td>Hospital discharge, avoid re-admissions.</td>
</tr>
</tbody>
</table>

Note: These instructions may be altered based on the patient’s specific conditions.

Fig. 2 (Continued).

thyroidectomy in a non-hyperfunctioning benign disease, daily doses of 1.6 mcg/Kg of levothyroxine are recommended for the first week. For patients over 65 years of age or cardiac patients, a lower initial dose is recommended. The objective is to maintain normal TSH figures at 4–6 weeks. Long-term hormone supplementation should be implemented by the endocrinologist and, once the dose has been adjusted, one annual determination of TSH would be sufficient. After a lobectomy, it is not necessary to start treatment, assessing the need for supplementation through TSH at 4–6 weeks. Due to the non-negligible percentage of patients with recurrence of nodular disease after hemithyroidectomy, an echographic and clinical control by a surgeon or endocrinologist would be advisable every 2 or 3 years. 148

During the hyperthyroidism postoperative period, antithyroid drugs will be suspended. Beta-blockers must be progressively reduced throughout one week. Substitution with levothyroxine may be started a week later at a dose of 1.7 mcg/kg. 44,149

In malignant conditions (differentiated thyroid cancer), the dose will depend on the disease stage, the intention to administer radioiodine and the way in which the TSH is intended to be stimulated. If ablation is not scheduled or if it is performed using recombinant TSH, substitution with levothyroxine at 1.6–2 mcg/kg will be started to achieve TSH
inhibition (<0.1 mUI/L). In the cases of high risk of recurrence, suppressive doses of TSH (<0.01 mUI/L) will be required.\(^{5,7,150,151}\) (LOE 2b, GR B).

In regards to the control of parathyroid function, if the patient has required a substitute treatment, a premature analytical control is recommended. Maximum doses of calcium and vitamin D require analytical control after 3 days or the reduction of the intake of calcitriol and/or oral calcium after 3 days and analytical control a week later. Lower doses allow for control after a week. A laboratory test with PTH is recommended a month after surgery to assess the recovery of the parathyroid function\(^{7,24,152–155}\) (LOE 2b, GR B).

The vocal function must be appraised. Even though there is some controversy and insufficient evidence, and it depends on availability in each centre, a postoperative laryngoscopy is advisable in all cases, especially if one has been preoperatively performed, as quality control of the units\(^9,156\) (LOE 5, GR D). It is essential in patients with preoperative motility alteration of the vocal cords, and in those with postoperative development of dysphonia, phonosthenia, bitonal voice or swallowing disorder or if an intraoperative neuromonitoring has been performed.

Clinical pathway for partial or total thyroidectomy.

Digestive system and general surgery department.

Expected hospital stay: 1 day (to balanced ASA I, II, and III patients).

Variations in the patient’s condition.
1. Uncontrolled pain.
2. Nausea with or without vomiting.
3. Vertigo.
4. Orthostatism.
5. Abundant haematic drainage or prolonged by drainages.
6. Cervical haematoma that does not require re-intervention.
7. Cervical haematoma that requires re-intervention.
8. Wound infection.
10. Symptomatic hypocalcaemia: paraesthesia, cramps, tetany.
11. Dysphonia.
12. Stridor.
15. Respiratory infection.
16. Fever <38°C without source.
17. Phlebitis.
18. DVT and/or pulmonary embolism.
19. Adverse effects of medication.
20. Death.

Variations depending on health care staff and people.
22. Physician’s decision, unscheduled tests request at the clinic.
23. Nurse’s decision.
24. Other health care professional’s decision.
25. Family’s decision.
26. Patient’s decision
27. Others. Specify.

Variations depending on the institution.
28. Laboratory delay.
29. Pharmacy delay.
30. Medical assistance delay.
31. Nurse assistance delay
32. Unavailability of operating room or cancelation of surgery
33. Rejection due to anaesthesia.
34. Others. Specify.

**Fig. 3 – Variations sheet.**
## Clinical Pathway for Thyroidectomy

### Time matrix. Chart that relates time (in divisions by days or hours) with actions and interventions performed on the patient: assessments and assistance, laboratory tests or determinations, medical treatments, nursing care, medication, activity, diet, information, admission or discharge criteria. It is attached in Fig. 2.

### Variations sheet. It gathers the variations that occurred from the original plan and the solution adopted. It assigns codes to the most relevant variations. It is gathered in Fig. 3.

**Patient's information sheet.** It provides information on the activities to be performed during the process. Its awareness increases collaboration and reduces the anxiety induced by the intervention (Fig. 4).

**Satisfaction survey.** It uses indicators of perception, assessment and improvement. Increasing patient satisfaction is not always more expensive. It is included in Fig. 5.

### Assessment indicators. A group of relevant indicators has been selected, defining their formula, type, justification, origin, exclusions, necessary clarifications and relevant include values, units, thresholds, deviations along with indications and actions to be implemented.

### Note: These instructions may be altered based on the patient's specific conditions.

---

**Clinical pathway for partial or total thyroidectomy.**

**Hospital .....................**

**Digestive system and general surgery department.**

**Expected hospital stay: 1 day (to balanced ASA I, II, and III patients).**

### Before admission | Day of surgery | The following day |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Activity.</strong></td>
<td>Before the intervention, you can walk as much as you want. Once you are admitted and receiving preoperative medication, you must stay in bed. Before going to the operating room, you must urinate, remove polish, make-up, nail polish, dentures and any metallic object. You must not take anything by mouth during the 6 hours prior to your surgery. You can take your usual medication with a sip of water and you can brush your teeth.</td>
<td>As of 6 hours after surgery, you can and must get up from the bed, seat on the chair and start walking. You will drink fluids as of 6 hours after your surgery is completed, progressing later to thick, easy-to-swallow food.</td>
</tr>
<tr>
<td><strong>Diet.</strong></td>
<td>You must not take anything by mouth during the 6 hours prior to your surgery. You can take your usual medication with a sip of water and you can brush your teeth.</td>
<td>You will drink fluids as of 6 hours after your surgery is completed, progressing later to thick, easy-to-swallow food.</td>
</tr>
<tr>
<td><strong>Medication.</strong></td>
<td>You will receive different medications before anaesthesia and surgery that will make your surgery safer and more comfortable. Your surgeon will prescribe analgesics. If you still feel pain, you can ask for additional analgesics. You will initially receive them intravenously and then orally.</td>
<td>When you wake up, you will be at a recovery room and you will have a mask over your mouth and nose to supply you with oxygen. You may also have a drainage in your neck. If a total thyroidectomy has been performed, a sample for blood tests will be extracted from you some hours after the surgery.</td>
</tr>
<tr>
<td><strong>Other treatments.</strong></td>
<td>An anaesthetist or nurse will visit you before the surgery. You will be placed on an venous line.</td>
<td></td>
</tr>
<tr>
<td><strong>Other instructions</strong></td>
<td>Your surgeon will inform you about what you can expect from the thyroidectomy and its potential complications (mainly haemorrhage, cervical haematoma, hoarseness due to recurrent nerve lesion and decrease in calcium blood level due to parathyroid glands lesion). Your surgeon or nurse will clear any doubts you might have in spite of this information. We will ask you to sign an informed consent document for the thyroidectomy.</td>
<td>Your surgeon or nurse will give you instructions about wound care. You must avoid rough neck extensions and movements, as well as “exaggerated” cough fits.</td>
</tr>
</tbody>
</table>

**Fig. 4 – Patient’s information sheet.** Note: These instructions may be altered based on the patient's specific conditions.
They are gathered in the supplementary material (Table 6 of Annex 1).

**Funding**

Support received for the performance of this study in the way of grants: none.

**Conflict of Interests**

None of the authors has received any funding related to the performance of this study or declares any conflict of interests.

**Appendix A. Supplementary Data**

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.cireng.2014.11.008.

---

**Fig. 5 – Patient and/or relative satisfaction survey.**

We are interested in using your opinions to improve our work.
Do you wish to make any additional suggestion? Please, tell us:

<table>
<thead>
<tr>
<th></th>
<th>1 Very satisfied</th>
<th>2 Dissatisfied</th>
<th>3 Regular</th>
<th>4 Satisfied</th>
<th>5 Very satisfied</th>
</tr>
</thead>
<tbody>
<tr>
<td>During the period in which you were admitted</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Did your stay coincide with what you were explained?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Information about your disease</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Information about the risks of the intervention</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Pain after surgical intervention</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Nausea or vomiting after surgical intervention</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>General appraising during admission</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

---

**REFERENCES**


110. Lecerf P, Ordy D, Perrodeau E, Lhommet C, Charretier C, Mor C, et al. Parathyroid hormone decline 4 hours after


